Tarsons Products Limited has informed the Exchange about Investor Presentation
An ISO 9001 & ISO 13485 Certified Company
Date: November 13, 2025
To, BSE Limited (“BSE”), Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
BSE Scrip code: 543399
To, National Stock Exchange of India Limited (“NSE”) “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE Symbol: TARSONS
Sub: Investor Presentation for the second quarter and half year ended September 30, 2025
Dear Sir/Madam,
Pursuant to the provisions of Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation for the second quarter and half year ended September 30, 2025.
The Presentation will also be uploaded on the Company’s website at www.tarsons.com.
We request you to kindly take the same on your records.
Thanking You,
Yours faithfully, For Tarsons Products Limited
Santosh Kumar Agarwal CFO, Company Secretary and Compliance Officer ICSI Membership No. A44836
Encl: As above
Tarsons Products Limited, 902, Martin Burn Business Park, BP-3, Sector –V, Salt Lake, Kolkata – 700091 Tel: +91 33 3522 0300, Web: www.tarsons.com Mail: info@tarsons.com, CIN: L51109WB1983PLC036510
TARSONS PRODUCTS LIMITED
Investor Presentation November 2025
TRUST DELIVERED
S a f e H a r b o r
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness
2
Q2 & H1FY26 Financial & Operational Highlights
Q 2 & H 1 F Y 2 6 K e y O p e r a t i o n a l H i g h l i g h t s
Revenue Mix : Geography Wise
Revenue Mix : Geography Wise
35%
32%
34%
32%
l
e n o a d n a t S
Q2FY25
Q2FY26
H1FY25
H1FY26
65%
68%
66%
68%
d e t a d
i l
o s n o C
47%
Q2FY25
53%
47%
Q2FY26
53%
48%
H1FY25
52%
47%
H1FY26
53%
Domestic
Overseas
4
Q 2 & H 1 F Y 2 6 S t a n d a l o n e F i n a n c i a l H i g h l i g h t s
Revenue (in Rs. crs)
EBITDA^ (in Rs. crs)
Profit After Tax (in Rs. crs)
Cash PAT# (in Rs. crs)
+5%
145.0
151.8
flat
80.1
80.5
+11%
23.5
26.1
+19%
48.4
40.5
-48%
19.4
+19%
48.0
+7%
40.3
10.1
24.9
26.7
-50%
12.9
6.5
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Gross Margin (%)
EBITDA Margin (%)
PAT Margin (%)
+140 bps
+50 bps
+320 bps
+390 bps
-800 bps
71.4%
72.8%
71.7%
72.2%
29.3%
32.5%
31.9%
16.1%
28.0%
-670 bps
13.4%
8.1%
6.7%
•
Impact on PAT due to accelerated depreciation and finance costs related to the new facilities at Panchla and Amta, with revenues expected to accrue in subsequent years.
• EBIDTA for H1FY26 grew by 19% on a Y-o-Y basis with margin expansion of 390 bps
• Cash PAT for H1FY26 grew by
19% on a Y-o-Y basis
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
#Cash PAT = PAT + Depreciation
^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit
5
Q 2 & H 1 F Y 2 6 C o n s o l i d a t e d F i n a n c i a l H i g h l i g h t s
Revenue (in Rs. crs)
EBITDA^ (in Rs. crs)
Profit After Tax (in Rs. crs)
Cash PAT# (in Rs. crs)
+5%
184.0
193.7
+3%
99.2
102.3
+8%
25.3
27.4
+18%
52.1
44.0
-64%
14.3
-68%
10.3
+21%
47.5
+6%
39.4
24.3
25.8
3.3
5.1
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Gross Margin (%)
EBITDA Margin (%)
PAT Margin (%)
+40 bps
+50 bps
+130 bps
+300 bps
-710 bps
67.1%
67.5%
67.2%
67.7%
25.5%
26.8%
23.9%
26.9%
10.4%
-510bps
7.8%
3.2%
2.6%
•
Impact on PAT due to accelerated depreciation and finance costs related to the new facilities at Panchla and Amta, with revenues expected to accrue in subsequent years.
• EBIDTA for H1FY26 grew by 18% on a Y-o-Y basis with margin expansion of 300 bps
• Cash PAT for H1FY26 grew by
21% on a Y-o-Y basis
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
Q2FY25
Q2FY26
H1FY25
H1FY26
#Cash PAT = PAT + Depreciation
^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit
6
B r i d g e b e t w e e n S t a n d a l o n e & C o n s o l i d a t e d P A T – H 1 F Y 2 6
(in Rs. crs)
10.1
-2.9
-1.9
1.4
5.1
-1.6
H1FY26 Standalone PAT
Interest Income and SBLC Amortisation eliminated at consolidation level
Interest paid to bank by subsidiary
Amortisation on intangible assets acquired
Nerbe PAT
H1FY26 Consolidated PAT
7
M a n a g e m e n t C o m m e n t a r y
Commenting on the performance, Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said:
“Consolidated Revenue for H1FY26 stood at ₹193.7 crore, reflecting a growth of 5.2% year-on-year. EBITDA grew by 18.4% YoY to ₹52.1 crore compared to ₹44.0 crore in H1FY25. PAT witnessed a decline primarily due to accelerated depreciation and higher finance costs arising from the capitalization of new facility at Panchla, whose revenue contribution will commence in the coming years. Cash PAT for H1FY26 stood at ₹47.5 crore, representing a robust 20.8% YoY growth.
With expanded capacities and the addition of new products, we expect to significantly increase our addressable market, driving sustained revenue growth in the years ahead. Backed by decades of experience in the plastic labware industry and the strong brand equity of Tarsons, we remain confident of a swift ramp-up of the new facilities from FY27 onwards, contributing meaningfully to overall revenue growth and margin expansion through operating leverage.
We remain committed to the long-term growth prospects of the industry and continue to invest through the current down cycle to strengthen our capacities and capabilities, positioning the company for sustainable growth over the next three to five years.”
Aryan Sehgal Promoter and Whole time Director
8
Q 2 & H 1 F Y 2 6 S t a n d a l o n e P r o f i t & L o s s S t a t e m e n t
Particulars (in Rs. Crs)
Q2FY26
Q2FY25
Revenue from Operations
Cost of Goods Sold
Gross Profit
Gross Margin (%)
Employee Cost
Other Expenses
EBITDA^
EBITDA Margin (%)
Depreciation
Other Income
EBIT
Finance Cost
Profit before Tax
Tax
Profit After Tax
PAT Margin (%)
EPS (Rs) Cash PAT#
80.5
21.9
58.6
72.8%
11.8
20.7
26.1
32.5%
20.2
7.3
13.3
4.4
8.9
2.3
6.5
8.1%
1.2
26.7
80.1
22.9
57.2
71.4%
10.9
22.8
23.5
29.3%
12.0
10.7
22.2
4.7
17.5
4.6
12.9
16.1%
2.4
24.9
Y-o-Y
0.5%
2.6%
150 bps
11.3%
320 bps
-40.1%
-49.3%
-49.5%
-800 bps
7.3%
H1FY26
H1FY25
151.8
42.3
109.5
72.2%
23.7
37.4
48.4
31.9%
37.9
11.9
22.3
8.7
13.7
3.6
10.1
6.7%
1.9
48.0
145.0
41.0
104.0
71.7%
21.6
41.9
40.5
28.0%
20.9
15.5
35.1
8.9
26.2
6.8
19.4
13.4%
3.6
40.3
Y-o-Y
4.7%
5.3%
40 bps
19.4%
390 bps
-36.4%
-47.9%
-47.9%
-670 bps
19.1%
#Cash PAT = PAT + Depreciation
9
^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit
Q 2 & H 1 F Y 2 6 C o n s o l i d a t e d P r o f i t & L o s s S t a t e m e n t
Particulars (in Rs. Crs)
Q2FY26
Q2FY25
Revenue from Operations
Cost of Goods Sold
Gross Profit
Gross Margin (%)
Employee Cost
Other Expenses
EBITDA^
EBITDA Margin (%)
Depreciation
Other Income
EBIT
Finance Cost
Profit before Tax
Tax
Profit After Tax
PAT Margin (%)
EPS (Rs) Cash PAT#
102.3
33.2
69.1
67.5%
17.8
23.8
27.4
26.8%
22.5
5.8
10.8
5.2
5.6
2.3
3.3
3.2%
0.6
25.8
99.2
32.6
66.6
67.1%
16.1
25.2
25.3
25.5%
14.0
8.4
19.7
4.8
14.9
4.6
10.3
10.4%
1.9
24.3
YoY
3.1%
3.7%
40 bps
8.4%
130 bps
-45.4%
-62.4%
-67.7%
-710 bps
6.1%
H1FY26
H1FY25
193.7
62.5
131.2
67.7%
35.7
43.3
52.1
26.9%
42.4
9.1
18.9
10.2
8.6
3.5
5.1
2.6%
1.0
47.5
184.0
60.3
123.7
67.2%
32.2
47.5
44.0
23.9%
25.0
11.3
30.3
9.1
21.2
6.9
14.3
7.8%
2.7
39.4
YoY
5.2%
6.0%
50 bps
18.4%
300 bps
-37.8%
-59.3%
-64.4%
-510 bps
20.8%
#Cash PAT = PAT + Depreciation
10
^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit
C o n s o l i d a t e d B a l a n c e S h e e t
Assets (in Rs. Crs)
Non-Current Assets
Property Plant & Equipment
CWIP
Other Intangible assets
Right of use assets
Goodwill
Financial Assets
Other Financial Assets
Current Tax Assets (Net)
Other Non Current Assets
Current Assets
Inventories
Financial Assets
(i) Trade receivables
(ii) Cash and cash equivalents
(iii) Bank balances other than (ii)
Other Financial Assets
Other Current Assets
Total Assets
Consolidated
Sep-25
Mar-25
909.6
504.1
251.0
29.7
16.9
32.5
7.4
3.9
64.1
254.1
135.4
72.5
25.9
5.4
0.1
14.8
837.5
455.1
232.9
31.7
16.7
32.5
4.5
3.5
60.5
242.6
126.0
79.6
25.1
0.5
0.1
11.2
Equity & Liabilities (in Rs. Crs)
Total Equity
Share Capital
Other Equity
Non-Current Liabilities
Financial Liabilities
(i) Borrowings
(ii) Lease Liabilities
(iii) Other Financial Liabilities
Provisions
Other Non Current Liabilities
Deferred Tax Liabilities
Current Liabilities
Financial Liabilities
(i) Borrowings
(ii) Trade Payables
(iii) Lease Liabilities
(iv) Other Financial Liabilities
Other Current Liabilities
Current tax liabilities (net)
Provisions
Consolidated
Sep-25
Mar-25
626.6
10.6
616.0
289.3
630.2
10.6
619.6
274.1
214.6
204.9
7.2
0.2
0.2
57.8
9.3
247.8
7.4
0.2
0.2
52.0
9.4
175.7
170.4
123.7
14.1
3.8
45.2
9.7
0.2
4.5
15.7
3.2
20.5
7.2
0.3
5.1
1,163.7
1,080.0
Total Equity & Liabilities
1,163.7
1,080.0
11
A b r i d g e d C o n s o l i d a t e d C a s h F l o w S t a t e m e n t
Particulars (in Rs. Crs)
Net Profit Before Tax
Adjustments for: Non -Cash Items / Other Investment or Financial Items
Operating profit before working capital changes
Changes in working capital
Cash generated from Operations
Direct taxes paid (net of refund)
Net Cash from Operating Activities
Net Cash from Investing Activities
Net Cash from Financing Activities
Net Decrease in Cash and Cash equivalents
Add: Cash & Cash equivalents at the beginning of the period
Exchange difference on translation of foreign currency
Cash & Cash equivalents at the end of the period
Consolidated
H1FY26
H1FY25
8.6
46.3
55.0
-6.6
48.3
-3.9
44.5
21.2
38.8
60.0
-25.1
34.9
-12.9
22.0
-78.3
-57.7
32.1
-1.7
25.1
2.5
25.9
38.6
2.8
17.1
0.0
20.0
• Net cash from operating
activities increased from 22 crs in H1FY25 to 44.5 crs in H1FY26, growth of more than 100% Y-o-Y, indicating efficient working capital management & cash conversion cycle
• Cash flow from operations / EBIDTA stood healthy at 85% compared to 50% in H1FY25
12
About Tarsons
T a r s o n s – a t a G l a n c e
*Approximately 9-12% as per Frost & Sullivan Industry Report 2021 #As per Frost & Sullivan Industry Report 2021
One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments)
Products used in laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies and hospitals
40+ years of experience in the life sciences industry delivering trusted high-quality products.
Robust market share in the highly fragmented Indian labware market*
Diversified product portfolio with 2,000+ SKUs across 350 product segments
6 vertically integrated manufacturing facilities in West Bengal
Pan-India distribution network with long-standing relationships with the distributors
One of the few players in India to have a global reach# in the labware market with 45+ authorized distributors & partners supplying products to over 40 countries
14
O u r J o u r n e y
Commenced production of Pipette Tips, thereby creating a high-quality import substitute
Pioneered the first fully robotic clean room plant for manufacturing molecular biology consumables
Established manufacturing facility expanding into production of fully automatic centrifuge tubes, and cryogenic vials in Dhulagarh
Established line for PCR products in Jalan Industrial Complex at Jangalpur
Product portfolio expansion & adding depth in existing product basket
Acquisition of European Entity Nerbe
Incorporation of TPPL with manufacturing of reusable plastic products
Expanded product line by initiating manufacturing of Centrifuge Tubes
Obtained ISO 9001:2015 certificate for manufacturing facility
Obtained ISO 13485:2016 / NSEN certificate for manufacturing facility
Acquired 5 acres land in Panchla & 6 acres land in Amta for capacity expansion, introduction of new product lines, backward integration & fulfillment center
Got listed on Stock Exchanges
1983
1984
1987
2002
2009
2012
2018
2019
2021 & 22
2024
15
L e a d i n g I n d i a n L a b w a r e S u p p l i e r
Trusted Brand for high quality products in the plastic labware market with 40+ years vintage in the industry
Expertise in production of a wide range of labware products & amongst the top 3 players with a robust market share*
Ability to offer differentiated, user friendly, reliable quality & cost-effective products has enabled strong brand recognition & customer loyalty
Individual product brands like Maxipense, Spinwin, Cryochill are well- recognized by the scientific community
Pioneered the first fully automated plant for manufacturing molecular biology consumables
In-house engineering team driving innovation & ensuring exceptional liquid handling performance across the liquid handling products
Source*: As per Frost & Sullivan Industry Report 2021
16
O u r C o m p e t i t i v e E d g e
Geographical Presence Wide geographic reach through a strong sales & distribution network
03
04
State of Art Facilities Well-equipped and advanced automation driven manufacturing facilities
02
Diversified Customers Long-standing relationships with a diverse set of key end-customers
01
Brand & Quality Leading Indian supplier to the life sciences sector with strong brand recognition and high-quality diversified products across varied customer segments.
Experienced Management Team Experienced promoter supported by a highly competent management team and backed by board of directors comprising of industry veterans
05
Financial Stability Financial track record with efficient capital allocation & streamlined operations ensuring consistent high profitability
06
17
C a t e r i n g t o d i v e r s i f i e d E n d U s e r I n d u s t r y …
Academic Institutes & Research Organization
National Centre for Biological Sciences
Indian Institute of Chemical Technology
Rain Forest Research Institute
KIIT University
Pharmaceutical Industry
Dr. Reddy's Laboratories Limited
Enzene Biosciences Limited
Contract Research Organization
Syngene International Limited
Veeda Clinical Research Limited
TCG Lifesciences Private Limited
Diagnostics Industry
Dr Lal Pathlabs Limited
Metropolis Healthcare Limited
Molbio Diagnostics Private Limited
Agappe Diagnostics Limited
Mylab Lifesolutions Private Limited
Exports Market
Avantor, Inc
FC-BIOS SDN BHD
iCell INC
Toei Kaisha
Toei Kaisha Limited
Measures to strengthen customer relations
Regular Feedback from Customers on quality, delivery & cost
Maintaining leading industry & Regulatory Compliance Standards
Product Customization as per the customer’s specific needs
Adherence to Quality standards & Safety Protocols in place
Wide Range of Products
50-member Sales Team with deeply entrenched relationships
18
1
2
3
4
5
6
O u r S t a t e - o f - t h e - a r t M a n u f a c t u r i n g F a c i l i t i e s …
Key Highlights of the High Precision Manufacturing Process
✓ Vertically integrated manufacturing capabilities with design &
development being carried out in-house
✓ Automated manufacturing with use of robotics & other
technologies developed in collaboration with overseas partners
Units
Burroshibtolla I
Burroshibtolla II
Kasba
Jangalpur
Dhulagarh
Panchla
Amta
Upcoming Facility
Land Area (in sq. mts.)
Ownership
Mfg. Revenue Contribution (FY25)
✓ Production process free from human touch & thus helps to achieve the desired levels of purity required for use in life sciences products
530
1,022
515
15,142
4,047
21,550
24,280
Leased
Leased
Leased
Owned
Leased
Owned
Owned
5.1%
6.3%
2.8%
59.1%
26.7%
-
-
✓ Manufactured in clean aseptic environment; manufacturing
process is carried out in fully-validated & 3rd-party certified ISO 8 clean rooms
✓ Quality Certifications: ISO & CE certifications
✓ In Amta, West Bengal, the Company is developing a new fulfillment center with in-house sterilization as well as manufacturing capability
✓ Company is expanding into new product categories and
capacity expansion at its new production facility in Panchla, West Bengal
19
… w i t h w i d e s p r e a d D o m e s t i c S a l e s & D i s t r i b u t i o n n e t w o r k …
Comprehensive Pan-India Distribution Network
Long-standing relationships with Distributors
North: 17% of FY25 Domestic Sales 42 Distributors
East: 13% of FY25 Domestic Sales 42 Distributors
West: 29% of FY25 Domestic Sales 23 Distributors
Data as on FY25
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness
South: 42% of FY25 Domestic Sales 38 Distributors
20
… w i t h h u g e u n d e r l y i n g E x p o r t M a r k e t P o t e n t i a l …
Huge Export Opportunity Market
One of the very few players to have a Global Reach
Demand for plasticware expected to grow at 10% CAGR for developing markets like APAC & MEA, developed markets like Americas & Europe also expected to grow healthy
✓ As of 31st March 2025, the company sold its products to 40+ countries via
45+ distributors
✓ Export operations are a blend of branded and ODM sales
✓ Under the ODM model, the product is independently designed & developed by the company as per the requirements given & then sold to the respective brand owners
Factors such as supplier reliability, cultivating new relationships, deepening existing relationships and meeting demands in timely manner will enhance the export market share
Rapid increase in demand for plasticware is providing platform for Indian players to expand share of export revenues while continuing import substitution at home
Export Revenue (INR mn)
Export Revenue Break-up (%)
998
FY19
FY25
480
35%
31%
65%
69%
Established Indian players can further expand export market share 0 on back of high-quality & reliable products with enhanced R&D and 4 independent design & customization capabilities
Domestic companies in India can take advantage of their competitive 0 pricing in order to capture larger share of global market 3
FY19
FY25
Branded
ODM
Key Overseas Clients (ODM Sales)
Toei Kaisha
21
… o f f e r i n g W i d e R a n g e o f H i g h - Q u a l i t y P r o d u c t s …
Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachable
Consumables
55.5% of FY25 Revenues
• Portfolio of products under this category
include: • Centrifuge ware • Cryogenic ware (tubes & accessories) • PCR consumables (tubes, plates, and
strips) • Petri dish • Pipettes
Reusables
40.7% of FY25 Revenues
• Portfolio of products under this category
include: • Bottles & Carboys • Beakers • Measuring cylinders • Racks • Others (jars, desiccators etc.) • High quality standards maintained to
ensure the products are leakage proof through specially designed lip-sealing geometry
Others
3.8% of FY25 Revenues
• Products under this category includes benchtop instrumentation such as:
• Vortex shakers • Centrifuges • Pipettors
• These products enable molecular works of cell collection, extraction, simple spin- down and f-tube separation
Offering a Wide Range of Products enabling its end-customers to source most of their product needs from a Single Source
22
… d i v e r s i f i e d p r o d u c t p o r t f o l i o o f P l a s t i c L a b w a r e
Pipette Tips
Centrifuge Tubes
Petri Dishes
Sterile Media Bottles
Cryo Vials
Storage Vials
Serological Pipette
5 2 Y F f o % 5 5 (
l
s e b a m u s n o C
) s e a S
l
5 2 Y F f o % 5 4 ( s r e h t O & s e b a s u e R
l
) s e a S
l
Mostly used research work transferring volume of with high precision
in for small liquids
Perfect for versatile these applications, are used for storage, spinning down & separation of colloidal solution
• Mostly used in culture of & microbes sensitivity assays
• Used once & discarded which optimizes time consumed in washing and sterilizing
Suited to preparation & of containment buffers, cultures or prolonged storage of pH sensitive liquids such as culture media
Used for storage of biological materials at temperatures as low -196°C (vapour phase of liquid nitrogen) to 121°C
as
Bottles
Carboys
Beakers
Cylinders
Designed for use with samples from - 80°C to 121°C. Used for storage of PCR reagents, enzymes & other diagnostics, biochemical reagents or samples
Disposable pipettes for tissue culture, microbiological and various research applications. Certified DNase, RNase, and Pyrogen free
Benchtop Instruments
for
• Used
containment, protection and transportation of various kinds of reagents • Leakproof, strong and durable
Used for media formulation and mixing, aseptic protocols, stirring and storage of intermediates
• Used for mixing; graduations are approximate and not liquid intended for accurate measurement
• Economical enough to discard after one use, or strong enough to reuse
Used to measure the volume of a liquids, chemicals, and solutions during daily lab work
include like vortex
• Wide variety products which
instrumentation
benchtop shakers, centrifuges, pipettors • Enable molecular works of
cell collection, extraction, simple spin-down 23 and f-tube separation
K e y B u s i n e s s S t r a t e g i e s
Key Business Strategies
• Focus on branding & promotion to enhance visibility in the labware industry to increase
brand awareness & loyalty
Enhance existing & expand product portfolio
• Manufacture New Products in the cell culture & robotic handled consumables and expand
into the import dominated markets of these products
• Leverage the advantage of “Make in India” and grow our domestic sales vis-à-vis exports
Enhance manufacturing capacities to leverage growth
Increasing presence in overseas markets
• Expand manufacturing capacities in popular product categories like liquid handling, centrifuge ware, & cryo ware through additional machines, moulds and ancillary infrastructure
• Acquired 5 acres of land to develop a new manufacturing facility in Panchla, West Bengal to
expand & enter into the new product segment comprising of cell culture
• Also, acquired 6 acres of land at Amta to develop fulfilment center, radiation facility and
manufacture few products
• Plans to export to ~120 countries in the next 5-10 years through the extensive experience
and proven track record of catering to overseas customers
• Acquired Nerbe, a Hamburg-based distributor specializing in plastic labware products • Two-pronged approach:
• Branded sales targeting emerging markets such as Asia Pacific, Middle East and South
America
• ODM sales to supply products to developed markets such as USA and Europe
Maintain operational efficiency & profitability
•
Implemented strategic cost-saving and efficiency improvement processes such as advanced automation solutions to improve productivity
• Continue to invest in automation in order to avoid human error & consequently improve
throughput
24
E x p e r i e n c e d B o a r d o f D i r e c t o r & M a n a g e r i a l T e a m
Sanjive Sehgal Chairman & Managing Director
• Chairman & Managing Director of
Tarsons Product Limited
• Has over 40 years of experience in
the company
Aryan Sehgal Promoter and Wholetime Director
• Whole-time Director of the
company
• Has over 10 years of experience
working in the company
Santosh Agarwal CFO & Company Secretary
• Qualified Chartered Accountant
& Company Secretary
• Has over 21 years of experience
Suresh Prabhala Non-Executive Director • Co-founder & Managing Partner at
•
ADV Partners. Investment professional with 25+ years of experience. Erstwhile ED and India Head for J.P. Morgan’s Asia Special Situations Groups
Girish Vanvari Independent Director
• Founder of Transaction Square, Tax, Regulatory & Business Advisory Firm • Qualified Chartered Accountant with in over 27 years of experience business consulting
Divya Momaya Independent Director • 22+
years of experience
in corporate and secretarial laws, corporate governance, business development
• Previously associated with BSE Ltd. And BSEL Infrastructure Realty Ltd.
Mr. Ramanathan Subramanian Arun Kumar Non-Executive Nominee Director
• Partner & COO at ADV Partners with 25 years of extensive experience in the financial services sector
• Served as Chief Operating Officer – MENA Investments (Bahrain), and Chief Financial Officer at the Sovereign Wealth Fund in Bahrain
at PineBridge
Dr. Monjori Mitra Independent Director
• MBBS degree from Burdwan University, • Pioneering researcher in the field of vaccines and plays a key role in several international advisory national and boards and working groups on immunization practice guidelines
Viresh Oberai Independent Director
• 22+ years experience with Tata Steel • Conferred with “Udyog Rattan” Indian Economics
from
award Society
25
C o n t r i b u t i o n t o w a r d s E n v i r o n m e n t a l , S o c i a l & G o v e r n a n c e
Clean room conditions eliminates all chances of contamination
Productivity optimisation with use of high automation
Use of Medical Grade Plastics. Products are designed to withstand critical use
NO litigations faced for pollution or degradation of environment over the past five years
NO impact of Climate change
Employee Welfare: Multi- pronged approach towards employee development.
Company has NOT witnessed any employee unrest / strikes or lockouts since inception
Some of the CSR activities has been directed towards TATA Cancer Hospital
The Board has an optimum combination of Executive and Non- Executive directors
Company has Clean Track Record of Liability payments to various stakeholders
Regular Review & Updation of policies for change requirements.
Whistleblower policy implemented
26
K e y T a k e a w a y s
Leading Indian manufacturer of labware with an established brand & focus on high-quality products
Financial profile with Historical strong EBITDA margins & high ROCE
Presence in an industry with double-digit growth potential and multiple growth drivers
Highly automated state-of-the-art manufacturing facilities churning out quality products
Long-standing relationships with 04 distributors catering to a diverse set of end-customers pan-India
Well-placed to grow domestic & export business through launch of new products & capacity expansion
27
Thank You
Tarsons Products Limited
CIN: L51109WB1983PLC036510 Mr. Santosh Agarwal – Chief Financial Officer santosh@tarsons.in
Strategic Growth Advisors Private Limited
CIN: U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98205 19303 / +91 98333 91899
www.gati.com | www.gatikwe.com
www.sgapl.net